Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) EBITDA Margin (2020 - 2022)

RAPT Therapeutics' EBITDA Margin history spans 3 years, with the latest figure at 2123.25% for Q2 2022.

  • For Q2 2022, EBITDA Margin fell 27538.0% year-over-year to 2123.25%; the TTM value through Mar 2023 reached 10291.76%, down 799950.0%, while the annual FY2022 figure was 5478.59%, 366288.0% down from the prior year.
  • EBITDA Margin for Q2 2022 was 2123.25% at RAPT Therapeutics, up from 3335.26% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 956.7% in Q2 2020 and bottomed at 3335.26% in Q1 2022.
  • The 3-year median for EBITDA Margin is 1627.25% (2020), against an average of 1730.04%.
  • The largest annual shift saw EBITDA Margin soared 5426bps in 2021 before it tumbled -198288bps in 2022.
  • A 3-year view of EBITDA Margin shows it stood at 997.39% in 2020, then tumbled by -141bps to 2404.76% in 2021, then rose by 12bps to 2123.25% in 2022.
  • Per Business Quant, the three most recent readings for RAPT's EBITDA Margin are 2123.25% (Q2 2022), 3335.26% (Q1 2022), and 2404.76% (Q4 2021).